Repurposing the antipsychotic trifluoperazine as an antimetastasis agent

Molecular Pharmacology

Volumn 87, Issue 3, 2015, Pages 501-512

  Pulkoski Gross, Ashleigh ^a   Li, Jian ^b   Zheng, Carolina ^a   Li, Yiyi ^a   Ouyang, Nengtai ^c   Rigas, Basil ^a   Zucker, Stanley ^a   Cao, Jian ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b JIMEI UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DOPAMINE 2 RECEPTOR; PROTEIN KINASE B; TRIFLUOPERAZINE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; 3T3 CELL LINE; ANIMAL; CHICK EMBRYO; DRUG EFFECTS; METABOLISM; MOUSE; PATHOLOGY; PREVENTION AND CONTROL; TUMOR CELL LINE; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CHICK EMBRYO; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; TRIFLUOPERAZINE;

EID: 84922155662     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.096941     Document Type: Article

References (57)

1. Ai Z, Fischer A, Spray DC, Brown AM, and Fishman GI (2000) Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest 105:161-171.
2. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, and Obrist P et al. (2007) The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:6979-6988.
3. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, and Korn WM (2003) Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 100:1943-1948.
4. Arnold SJ, Stappert J, Bauer A, Kispert A, Herrmann BG, and Kemler R (2000) Brachyury is a target gene of the Wnt/β-catenin signaling pathway. Mech Dev 91:249-258.
5. Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Albertelli M, Culler MD, Motta M, Minuto F, and Magni P et al. (2010) Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. J Endocrinol 207:309-317.
6. Barker N and Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5:997-1014.
7. Basu B, Sarkar C, Chakroborty D, Ganguly S, Shome S, Dasgupta PS, and Basu S (2010) D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem 285:27026-27032.
8. Beaulieu J-M and Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182-217.
9. Bissell MJ and Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46-54.
10. Bissell MJ, Weaver VM, Lelièvre SA, Wang F, Petersen OW, and Schmeichel KL (1999) Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 59(7, Suppl)1757-1764s.
11. Boon EM, van der Neut R, van de Wetering M, Clevers H, and Pals ST (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62:5126-5128.
12. Cao J, Rehemtulla A, Bahou W, and Zucker S (1996) Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 271:30174-30180.
13. Comen E and Norton L (2012) Self-seeding in cancer. Recent Results Cancer Res 195:13-23.
14. Deryugina EI and Quigley JP (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130:1119-1130.
15. Dufour A, Sampson NS, Zucker S, and Cao J (2008) Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 217:643-651.
16. Evensen NA, Li J, Yang J, Yu X, Sampson NS, Zucker S, and Cao J (2013) Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery. PLoS ONE 8:e82811.
17. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, and Lu Z (2007) Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity. J Biol Chem 282:11221-11229.
18. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, and Palena C (2010) The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 120:533-544.
19. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611.
20. Friedl P and Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147:992-1009.
21. Gupta SC, Sung B, Prasad S, Webb LJ, and Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34:508-517.
22. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
23. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK, and Labhasetwar V (2008) 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 5:849-862.
24. Howe LR, Watanabe O, Leonard J, and Brown AM (2003) Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63:1906-1913.
25. Hsieh CH, Chao KS, Liao HF, and Chen YJ (2013) Norcantharidin, derivative of cantharidin, for cancer stem cells. Evid Based Complement Alternat Med 2013:838651.
26. Huang W, Sherman BT, and Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1-13.
27. Huang W, Sherman BT, and Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57.
28. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, and MassaguéJ (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315-1326.
29. Leaf C and Burke D (2004) Why We're Losing The War On Cancer [And How To Win It]. Fortune 145:1.
30. LeBleu VS, Macdonald B, and Kalluri R (2007) Structure and function of basement membranes. Exp Biol Med (Maywood) 232:1121-1129.
31. Marques LO, Lima MS, and Soares BG (2004) Trifluoperazine for schizophrenia. Cochrane Database Syst Rev (1):CD003545.
32. Norton L and Massagué J (2006) Is cancer a disease of self-seeding? Nat Med 12:875-878.
33. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, and Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9 :203-214.
34. Peng CC, Chyau CC, Wang HE, Chang CH, Chen KC, Chou KY, and Peng RY (2013) Cytotoxicity of ferulic Acid on T24 cell line differentiated by different microenvironments. Biomed Res Int 2013:579859.
35. Polischouk AG, Holgersson A, Zong D, Stenerlöw B, Karlsson HL, Möller L, Viktorsson K, and Lewensohn R (2007) The antipsychotic drug trifluoperazine inhibits DNA repair and sensitizes non small cell lung carcinoma cells to DNA double-strand break induced cell death. Mol Cancer Ther 6:2303-2309.
36. Redig AJ and McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113-126.
37. Ribatti D, Nico B, Vacca A, and Presta M (2006) The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 1:85-91.
38. Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, and Djonov V (2001) Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and antiangiogenesis in vivo. Anat Rec 264:317-324.
39. Sachlos E, Risuẽo RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, and Graham M et al. (2012) Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149:1284-1297.
40. Sánchez-Tilló E, de Barrios O, Siles L, Cuatrecasas M, Castells A, and Postigo A (2011) β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 108:19204-19209.
41. Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, and Katz S et al. (2012) Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 122:2637-2651.
42. Sullivan GF, Garcia-Welch A, White E, Lutzker S, and Hait WN (2002) Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J Exp Ther Oncol 2:19-26.
43. Sun X, Rogoff HA, and Li CJ (2008) Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 26:1379-1382.
44. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, Lemieux M, Carrasco DE, Ryan J, and Horst D et al. (2012) Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4: 148ra117.
45. Takahashi-Yanaga F and Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16:3153-3162.
46. Talmadge JE and Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70 :5649-5669.
47. Tetsu O and McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
48. Thakur R and Mishra DP (2013) Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med 17:449-456.
49. Tonini T, Rossi F, and Claudio PP (2003) Molecular basis of angiogenesis and cancer. Oncogene 22:6549-6556.
50. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, Kudo-Saito C, Fujita T, Sumimoto H, and Kawakami Y (2012) Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol 189:2110-2117.
51. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, and Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939.
52. Yeh C-T, Wu ATH, Chang PM-H, Chen K-Y, Yang C-N, Yang S-C, Ho C-C, Chen C-C, Kuo Y-L, and Lee P-Y et al. (2012) Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 186:1180-1188.
53. Zacharski LR, Moritz TE, Haakenson CM, O'Donnell JF, Ballard HS, Johnson GJ, Ringenberg QS, Schilsky RL, Spaulding MB, and Tornyos K et al. (1990) Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest 8:451-458.
54. Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S, and Cao J (2011) Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 286:33167-33177.
55. Zhang X, Gaspard JP, and Chung DC (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61:6050-6054.
56. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y, and Baba Y (2004) Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 53:267-275.
57. Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M, and Bahou WF (1995) Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 270:23730-23738.